Literature DB >> 15176537

Transcatheter embolization as primary treatment for visceral pseudoaneurysms in pancreatitis: clinical outcome and imaging follow up.

Hemant Deshmukh1, Krantikumar Rathod, Ashwin Garg, Rahul Sheth, Suyash Kulkarni.   

Abstract

BACKGROUND: Pseudoaneurysm formation is an uncommon but fatal complication of pancreatitis. The morbidity and mortality associated with surgical management is high. Transcatheter embolization is a definitive minimally invasive form of treatment. AIM: To review our experience with transcatheter embolization as a therapeutic modality for pseudoaneurysms complicating pancreatitis.
METHODS: This retrospective analysis included data of 30 patients (mean age 37 years, range 25 to 65; 24 men) with visceral pseudoaneurysms secondary to pancreatitis, who underwent diagnostic angiography and transcatheter embolization, during the period March 1993 to February 2003.
RESULTS: In 29 patients the pseudoaneurysms were successfully isolated from the circulation, and hemostasis was achieved. Re-bleeding occurred in one patient, for which re-embolization was done. Twenty-nine patients improved clinically. One patient in whom the pseudoaneurysm was successfully embolized died due to septicemic shock.
CONCLUSION: Endovascular embolization is a safe and effective non-surgical modality of treatment for visceral pseudoaneurysms complicating pancreatitis.

Entities:  

Mesh:

Year:  2004        PMID: 15176537

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  2 in total

1.  Pseudoaneurysm of the replaced right hepatic artery with arterio venous fistula to the portal vein.

Authors:  Arun Wesley Solkar David; Thomas Mammen; Philip Joseph; Venkatramani Sitaram
Journal:  Indian J Surg       Date:  2008-05-21       Impact factor: 0.656

2.  Endovascular embolization of arterial bleeding in patients with severe acute pancreatitis.

Authors:  Min Ai; GuangMing Lu; Jian Xu
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-07-25       Impact factor: 1.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.